Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

European Commission approves Sibnayal for distal renal tubular acidosis

May 5, 2021

Topline data presented from first cohort of phase Ib trial of RGLS-4326

May 4, 2021

FDA approves Farxiga for chronic kidney disease

May 3, 2021

Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes

April 12, 2021

X-Chem discloses new HAOX1 inhibitors

April 8, 2021

First patient dosed in phase II AFFINITY basket study of atrasentan

April 8, 2021

FDA approves Myrbetriq tablets and granules for neurogenic detrusor overactivity in children

March 26, 2021

New hydroxyacid oxidase 1 inhibitors discovered at OxaluRx

March 18, 2021

Renibus initiates phase II trial of RBT-1 for prevention of AKI

March 12, 2021

Phase III study of sparsentan in FSGS achieves interim proteinuria endpoint

Feb. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...